Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25042061 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Angela Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Virus Diseases, Cyclodextrins, beta-Cyclodextrins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Science Foundation, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
The emergence and mutation of pathogenic viruses have been occurring at an unprecedented rate in recent decades. The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global public health crisis due to extensive viral transmission. In situ RNA mapping has revealed angiotensin-converting enzyme 2 (ACE2) expression to be highest in the nose and lower in the lung, pointing to nasal susceptibility as a predominant route for infection and the cause of subsequent pulmonary effects. By blocking viral attachment and entry at the nasal airway using a cyclodextrin-based formulation, a preventative therapy can be developed to reduce viral infection at the site of entry. Here, we assess the safety and antiviral efficacy of cyclodextrin-based formulations. From these studies, hydroxypropyl beta-cyclodextrin (HPBCD) and hydroxypropyl gamma-cyclodextrin (HPGCD) were then further evaluated for antiviral effects using SARS-CoV-2 pseudotypes. Efficacy findings were confirmed with SARS-CoV-2 Delta variant infection of Calu-3 cells and using a K18-hACE2 murine model. Intranasal pre-treatment with HPBCD-based formulations reduced viral load and inflammatory signaling in the lung. In vitro efficacy studies were further conducted using lentiviruses, murine hepatitis virus (MHV), and influenza A virus subtype H1N1. These findings suggest HPBCD may be used as an agnostic barrier against transmissible pathogens, including but not limited to SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA.
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA.
- Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90007, USA.
- Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
ORCID-Profile: Angela Lu, Brandon Ebright, Jean-Marie C Bouteiller, Stan G Louie, Isaac Asante
Förderung
- NHLBI NIH HHS
- National Science Foundation
- National Heart Lung and Blood Institute
- the USC Roski Eye Institute, and the USC Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics
Zitieren
APA
Lu, A., Ebright, B., Naik, A., Tan, H. L., Cohen, N. A., Bouteiller, J. C., Lazzi, G., Louie, S. G., Humayun, M. S., & Asante, I. (2024). Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042061
Vancouver
Lu A, Ebright B, Naik A, Tan HL, Cohen NA, Bouteiller JC, et al. Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042061
BibTeX
@article{Lu2024,
author = {Lu, Angela and Ebright, Brandon and Naik, Aditya and Tan, Hui L and Cohen, Noam A and Bouteiller, Jean-Marie C and Lazzi, Gianluca and Louie, Stan G and Humayun, Mark S and Asante, Isaac},
title = {Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25042061}
}
EUVIMED